Evaluation of fluconazole in the treatment of oropharyngeal candidiasis in patients with AIDS

Infections in Medicine

Volumn 13, Issue 8, 1996, Pages 708-713

  Quart, Arthur M ^a   Espinel Ingroff, Ana ^b   Moore, Lynn Steele ^c   Reich, Daniel ^d  

^a North Central Bronx Hospital   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL CENTER OF DELAWARE   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

AIDS; antifungal agents; candidiasis; fluconazole

Indexed keywords

FLUCONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANDIDIASIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; OROPHARYNX;

EID: 0029818190     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Marriott DJ, Jones PD, Hoy JF, et al: Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. Med J Aust 158:312-316, 1993.
2. Stevens DA, Greene SI, Lang OS: Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Arch Intern Med 151:2458-2464, 1991.
3. Klein RS, Harris CA, Small CB, et al: Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 311:354-358, 1984.
4. Quintiliani R, Owens NJ, Quercia RA, et al: Treatment and prevention of oropharyngeal candidiasis. Am J Med 77 (suppl 4D):S44-S48, 1984.
5. Hay RJ: Overview of studies of fluconazole in oropharyngeal candidiasis. Rev Infect Dis 12(suppl 3):S334-S337, 1990.
6. Meunier F, Aoun M, Gerard M: Therapy for oropharyngeal candidiasis in the immunocompromised host: A randomized double-blind study of fluconazole vs. ketoconazole. Rev Infect Dis 12(suppl 3):S364-S368, 1990.
7. Thorsen S, Mathiesen LR: Fluconazole for ketoconazole-resistant oropharyngeal candidiasis in HIV-1 infected patients. Scand J Infect Dis 22:375-376, 1990.
8. Epstein JB, Truelove EL, Izutzu KT: Oral candidiasis: Pathogenesis and host defense. Rev Infect Dis 6:96-106, 1984.
9. Ackerman Z, Zeltser R, Maayan S: AIDS and oropharyngeal candidiasis. Isr J Dent Sci 2:162-166, 1989.
10. Dupont B, Drouhet E: Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycol 26:67-71, 1988.
11. Chave JP, Cajot A, Bille J, et al: Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: A pilot study. J Infect Dis 159:806-807, 1989.
12. Koletar SL, Russell JA, Fass RJ, et al: Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 34:2267-2268, 1990.
13. Leen CLS, Dunbar EM, Ellis ME, et al: Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: A double-blind placebo-controlled study. J Infect 21:55-60, 1990.
14. Blum RA, D'Andrea DT, Florentino BM, et al: Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 114:755-757, 1991.
15. Brammer KW, Tarbit MH: A review of the pharmacokinetics of fluconazole (UK-49,858) in laboratory animals and man, in Fromtling RA (ed): Recent Trends in the Discovery, Development and Evaluation of Fungal Agents. Barcelona, Spain, J.R. Prous, 1987, pp 141-149.
16. Bozzette SA, Larsen RA, Chiu J, et al: A placebo-controlled trial of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 324:580-584, 1991.
17. Sobel JD: Fluconazole maintenance therapy in recurrent vulvovaginal candidiasis. Int J Gynaecol Obstet 37(suppl 1):S17-S24, 1992.
18. Walsh TJ, Lee J, Aoki S, et al: Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis 12(suppl 3):S307-S317, 1990.
19. Walsh TJ, Foulds G, Pizzo PA: Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrob Agents Chemother 33:467-469, 1989.
20. Richardson K, Brammer KW, Marriott MS, et al: Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 27:832-835, 1985.
21. Lazar JD, Hilligoss DM: The clinical pharmacology of fluconazole. Semin Oncol 17(suppl 6):S14-S18, 1990.
22. Thorpe JE, Baker N, Bromet-Petit M: Effect of oral antacid administration on the pharmacokinetics of oral fluconazole. Antimicrob Agents Chemother 34:2032-2033, 1990.
23. Quart AM, Espinel-Ingroff A, Reich D: Fluconazole for refractory oropharyngeal candidiasis in AIDS patients. AIDS Patient Care 9:56-59, 1995.
24. Quart A: Oral candidiasis: An early clue and persistent symptom of HIV infection. Mod Med Asia 61:36-45, 1993.
25. Lim SG, Lee CA, Hales M, et al: Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs. Aliment Pharmacol Ther 5:199-205, 1991.
26. Esposito R, Castagna A, Foppa CU: Maintenance therapy of oropharyngeal candidiasis in HIV-infected patients with fluconazole. AIDS 4:1033-1034, 1990.
27. DeWit S, Weerts D, Goossens H, et al: Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1:746-748, 1989.